Transgene to Present Data on its Two Therapeutic Cancer Vaccines at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Presentations include new data further demonstrating the immune responses induced by TG4001 and recently updated results from the adjuvant Phase I trial of neoantigen vaccine TG4050 in head and neck cancer

Strasbourg, France, May 26, 2023, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced two poster presentations at the 2023 American Association of Clinical Oncology (ASCO) annual meeting to be held in Chicago, IL (June 2-6).

The posters will highlight that in challenging clinical settings:

• TG4001 induced T-cell responses against HPV16 antigens in the ongoing Phase II trial.
• TG4050: 100% of the patients treated with the individualized therapeutic cancer vaccine developed multiple functional T cell responses against targeted neoantigens, which may be associated with an improved outcome in patients with head and neck cancer in the adjuvant setting.

Details for the presentations are as follows:

TG4001

Abstract Title: Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.

Abstract Number: 2630

Session Title: Developmental Therapeutics—Immunotherapy

Session Date and Time:  Saturday, June 3, 2023, 8:00 AM-11:00 AM (CDT)

Link to the abstract: click here

TG4050

Abstract Title: Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.

Abstract Number: 6082

Session Title: Head and Neck Cancer

Session Date and Time: Monday, June 5, 2023, 1:15 PM-4:15 PM (CDT)

Link to the abstract: click here

The abstracts are available on Transgene’s website.